DBV Technologies Shares at €3.44: Up 77% Over the Year, Heading to the June 3rd General Meeting

An Intraday Rebound that Leaves the Stock Below its Short-Term Moving Averages

DBV Technologies shares are priced at €3.44 following yesterday's decline, in a well-oriented Parisian market. The stock ranks 29th in the SBF 120 during the session, not among the index's top gainers. Today's rebound is not enough to push the price above its short averages. The 20-day moving average (MM20) at €3.48 remains 1.15% above the current price, the 50-day moving average (MM50) at €3.56 is 3.37% above, while the 200-day moving average (MM200) at €2.85 maintains a favorable gap of over 20%, reflecting the rally accumulated over the year. The RSI at 44 remains in the neutral zone and the price moves in the lower part of the Bollinger Bands, at 40% of the range. The support at €3.34 contained Wednesday's decline.

Busy Regulatory Calendar and Shareholder Meeting on June 3rd

The biotech is entering a busy period on the corporate front. The mixed general meeting is scheduled for June 3rd, marking the first milestone of the financial calendar, followed by the half-year results expected on July 29th. In the background, the regulatory calendar remains a central issue. The company confirmed in early May two biologics license application filings this year for its Viaskin Peanut patch, one for children aged 4 to 7, and another for toddlers aged 1 to 3. The cash reserves of $229 million reported at the end of March cover financial needs until the second quarter of 2027. On the analysts' opinions front, Kempen lowered its price target from €11 to €9 in early May while maintaining a buy recommendation. The next concrete event for shareholders is therefore the June 3rd meeting.